Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.32 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.32 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PTGFR | P43088 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5672566 | 0.89 | PYCR1 (0.35) | LMNASMN1; SMN2NPSR1PTGER1CCR5 | |
| SCHEMBL6298659 | 0.88 | PYCR1 (0.35) | LMNASMN1; SMN2NPSR1PTGER1CCR5 | |
| SCHEMBL17159412 | 0.85 | LMNA (0.37) | LMNASMN1; SMN2PTGER1CCR5HTR6 | |
| SCHEMBL7015152 | 0.84 | SYK (0.37) | SMN1; SMN2SLC6A4ALDH1A1HTR2AHTT | |
| SCHEMBL30516569 | 0.82 | KDM5A (0.36) | LMNASMN1; SMN2PTGER1CCR5ALDH1A1 | |
| SCHEMBL6132650 | 0.82 | KDM5A (0.36) | LMNASMN1; SMN2PTGER1CCR5ALDH1A1 | |
| SCHEMBL7013760 | 0.80 | MRGPRX4 (0.34) | LMNAHTTSLC16A3SLC16A1MCTS1 | |
| SCHEMBL14126456 | 0.80 | NQO2 (0.35) | LMNASMN1; SMN2PTGER1ALDH1A1GAA | |
| SCHEMBL31533391 | 0.79 | ABL1 (0.42) | LMNAPTGER1CCR5ALDH1A1HTT | |
| SCHEMBL195484 | 0.79 | SLC6A4 (0.36) | LMNASMN1; SMN2NPSR1PTGER1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180282363-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-10-04 | — | — | US | disclosed |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8785403-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8785403-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8575114-B2 | SGLT-2 inhibitors, methods of making them, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575114-B2 | SGLT-2 inhibitors, methods of making them, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-10-11 | — | — | US | disclosed |
| US-8202984-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20110237527-A1 | SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237527-A1 | SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-7943788-B2 | Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943788-B2 | Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20050233988-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | LMNA 1887/4885SMN1; SMN2 3474/4885NPSR1 3024/4885 |
| US-20050233988-A1 | Novel compounds | CYP1B1, CYP4B1, CYP2B6 | LMNA 1753/4885SMN1; SMN2 3266/4885NPSR1 768/4885 |
| US-20110237527-A1 | SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | SLC5A2, SLC5A1, SLC10A1 | LMNA 2114/4885SMN1; SMN2 2406/4885NPSR1 3722/4885 |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | LMNA 1887/4885SMN1; SMN2 3474/4885NPSR1 3024/4885 |
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | LMNA 1887/4885SMN1; SMN2 3474/4885NPSR1 3024/4885 |
| US-20180282363-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | LMNA 1887/4885SMN1; SMN2 3474/4885NPSR1 3024/4885 |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | LMNA 1887/4885SMN1; SMN2 3474/4885NPSR1 3024/4885 |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | LMNA 1887/4885SMN1; SMN2 3474/4885NPSR1 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.